Publications by authors named "C Marquetand"
Background: In the randomized SOLVE-TAVI (compariSon of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthesia in Transcatheter Aortic Valve Implantation) trial comparing newer-generation self-expanding valves (SEV) and balloon-expandable valves (BEV), as well as conscious sedation (CS) and general anesthesia (GA), clinical outcomes were similar both for valve and anesthesia comparison at 30 days and 1 year.
View Article and Find Full Text PDFBackground And Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended in acute myocardial infarction (AMI) for bailout treatment in case of angiographic microvascular obstruction (MVO), also termed no-reflow phenomenon, after percutaneous coronary intervention (PCI) with, however, lacking evidence (class IIa, level C).
Methods: The investigator-initiated, international, multicentre REVERSE-FLOW trial randomized 120 patients with AMI and thrombolysis in myocardial infarction flow grade ≤ 2 after primary PCI to optimal medical therapy with or without GP IIb/IIIa inhibitor. The primary endpoint was infarct size [percentage of left ventricular (LV) mass assessed by cardiac magnetic resonance (CMR).
Article Synopsis
- * Methods: A literature review yielded 19 studies involving 6,509 RHC procedures, focusing on the overall and access-related complications as the main measure of success.
- * Results: Peripheral venous access (PVA) showed a lower complication rate (0.1%) compared to central venous access (CVA, 1.2%), suggesting that PVA is the preferred method for RHC despite some uncertainty in the data.
Interventional closure of an iatrogenic LAA-perforation by means of a PFO-occluder.
Catheter Cardiovasc Interv
October 2024
Article Synopsis
- * An 87-year-old patient undergoing elective LAA closure experienced a rare but serious complication—pericardial effusion—leading to cardiac arrest, which required CPR.
- * The complication was resolved by sealing the perforation with a PFO-occluder, demonstrating that serious issues during procedures can sometimes be treated with interventional techniques, avoiding more invasive surgeries.
Background: Besides transcatheter edge-to-edge repair (TEER), there are new interventional treatment options for mitral and tricuspid regurgitation in evaluation, such as a complete replacement of the valve through a prosthesis.
Case Summary: A 78-year-old previous coronary artery bypass graft-operated patient with symptomatic severe mitral regurgitation and tricuspid regurgitation was sequentially treated by a transfemoral transcatheter mitral and tricuspid valve prosthesis (Cardiovalve; Cardiovalve Ltd, Israel) due to unfavourable mitral valve anatomy. The transcatheter mitral valve implantation (TMVI) was performed first and after progression of the tricuspid regurgitation, a second transcatheter valve prosthesis was implanted in tricuspid position (TTVI) 1.